Full 12-month data from Ocugen’s phase 2 eye disease gene therapy show the therapy significantly reduces the size of lesions, ...

Ocugen Inc. OCGN shares are down during Tuesday’s session following topline data from its Phase 2 ArMaDa trial of OCU410.

OCGN's gene-agnostic eye therapy aims to treat multiple retinal mutations, with key filings and pivotal data in 2026???2027 set to test its broad platform.

Ocugen (OCGN) stock drops after updated mid-stage trial data for its gene therapy targeting an eye disorder called geographic ...

Medium-dose OCU410 met the 12-month primary endpoint, reducing GA lesion growth by 31% versus control (P < .05), with ...

Hot on the heels of a $150 million fundraise, Atsena Therapeutics is back with early-stage data for the company’s eye disease gene therapy. The candidate improved the structure and function of the ...

Add Yahoo as a preferred source to see more of our stories on Google. Duke Eye Center has become the first academic medical center in the country to implant a new cell-based gene therapy for a rare ...

The first study to evaluate both eyes treated with a gene therapy targeting neovascular, or wet, age-related macular degeneration (AMD) has found the treatment as safe and effective in the second eye ...

Scientists at Oregon Health & Science University's Casey Eye Institute and Baylor College of Medicine's Cullen Eye Institute published findings from a two-year Phase I clinical trial in the journal ...

A genetic variant carried by at least one-fifth of the population may do far more than raise the odds of developing Alzheimer ...

The UC Davis Department of Ophthalmology has received a five-year, $3.6 million grant from the National Eye Institute to explore a new way to treat vision loss using gene therapy. The research could ...